BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
0.2132
-0.0021 (-0.98%)
At close: Aug 24, 2026, 4:00 PM EDT
0.2195
+0.0063 (2.95%)
Pre-market: Aug 25, 2026, 4:01 AM EDT

BioRestorative Therapies Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.360.360.40.150.120.05
Revenue Growth
-8.47%-10.30%175.03%21.70%160.44%-40.26%
Gross Profit
0.330.340.370.150.120.05
Operating Income
-14.23-15.65-11.56-15.22-18.97-26.31
Net Income
-11.06-14.24-8.98-10.42-13.22-44.3
Earnings Per Share
-0.98-1.58-1.16-2.47-3.65-37.30
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3.592.9510.7311.0714.7521.03
Total Debt
0.030.04-0.160.30.67
Net Cash (Debt)
3.562.9110.7310.914.4520.36
Net Cash Growth
-60.90%-72.88%-1.57%-24.53%-29.03%-
Net Cash Per Share
0.310.321.382.583.9917.14

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-11.82-10.79-8.23-6.43-5.91-3.33
Capital Expenditures
-0.08-0.12-0.11-0.17-0.27-0.03
Free Cash Flow
-11.9-10.91-8.34-6.6-6.18-3.36
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
92.09%93.37%93.00%100.00%100.00%100.00%
Operating Margin
-3975.00%-4350.05%-2881.60%-10439.49%-15838.08%-57191.03%
Pretax Margin
-3089.55%-3959.40%-2239.25%-7145.20%-11036.97%-96311.51%
Profit Margin
-3089.55%-3959.40%-2239.25%-7145.20%-11036.98%-96311.51%
FCF Margin
-3324.57%-3031.70%-2078.94%-4527.61%-5157.20%-7305.58%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
15.1829.0024.6856.1784.33329.56